Cervical Cancer screening program in Hyderabad and surrounding peri-urban areas, South India: prevalence of high risk HPV subtypes by Thumoju, Sravya et al.
  
 
Ivy Union Publishing | http: //www.ivyunion.org December 10, 2016 | Volume 4 | Issue 1  
Thumoju S et al. American Journals of Cancer Biology 2016, 4:6-15 
7 
6 
Page 1 of 10 
 
 
Cervical Cancer Screening Program in Hyderabad and 
Surrounding Peri-urban Areas, South India: Prevalence of 
High Risk HPV Subtypes  
Sravya Thumoju
1
, Mohammed Khaliq Mohiuddin
1,2
, Chandrashekhar Sirumalla
4
,
 
Vittel Uma Rani 
6
, Mahjabeen Salma
 5
, Yog Raj Ahuja
1
, Qurratulain Hasan
1,2
, Vasavi Mohan
1,2,3* 
 
1 Department of Genetics and Molecular Medicine,  
Vasavi Medical and Research Centre, Hyderabad, India 
2 Department of Genetics and Molecular Medicine, Kamineni Hospitals, Hyderabad, India 
3 Hansgene Cancer Foundation, Hyderabad, India 
4 Department of Pathology, Kakatiya Medical College, Warangal, India 
5 Department of Pathology, Yashoda Hospitals, Hyderabad, India 
6 Department of Gynaecology, Vasavi Medical and Research Centre, Hyderabad, India 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   
Research Article 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Cervical; Pap cytology; HPV; High-risk subtypes  
Received: November 1, 2016; Accepted: November 24, 2016; Published: December 10, 2016 
Competing Interests: The authors have declared that no competing interests exist.  
Copyright: 2016 Mohan V et al. This is an open-access article distributed under the terms of the Creative Commons 
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original 
author and source are credited. 
*Correspondence to: Vasavi Mohan, Department of Genetics and Molecular Medicine, Vasavi Medical and Research 
Centre, Hyderabad, Inida 
E-mail: greenpastures@gmail.com 
Abstract  
Our work was aimed at (I) identifying women with abnormal cervix upon visual inspection and pap cytology 
testing (II) determining the presence of HPV infection in the individual, along with sub-typing in severe 
pathologies and cancer, which is an established risk factor for cervical malignancy reported world-over. 
A total of 530 eligible women were screened. Our program witnessed an incremental increase in the number of 
women accessing screening after counselling for awareness of the importance of testing. 1.8% of our subjects 
showed the presence of high-risk HPV subtypes; all of them were associated with an abnormal Pap cytology. 
HPV was shown to be associated with an infectious pap, RCC, ASCUS, HSIL, SCC (p<0.05) when compared to 
normal cytology (p=0.05). Awareness and the importance of cervical examination is low. Health camps need to 
focus on counselling subjects about its benefits to improve their participation and ensure success of screening 
programs. The significant association of HPV infection with abnormal pathologies (p=0.05) and the presence of 
hr-HPV subtypes other than 16 and 18 draws attention to the need to evaluate the subtypes prevalent in our 
population and apply this information to cervical vaccination schemes. 
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Introduction 
Cervical cancer is a potentially preventable gynecological malignancy. It is the second most frequent cancer affecting 
women with reports of rise in prevalence from different parts of the country. With 5,28,000 new cases every year, 
cervical cancer is the fourth most common cancer affecting women worldwide (2,66,000 deaths in 2012). Almost 70% 
of the global burden falls in developing countries; more than one-fifth of all new cases are diagnosed in India (WHO, 
2013) [1,2]. The disease consumes resources in the way of medical spending, lost productivity and like with other 
cancers, disturbing the family structure and dependents [3]. The execution of systematic cytology-based screening 
programs along with efficient follow-ups can greatly reduce the incidence and mortality of cervical cancer [4]. 
The conventional method of cervical cancer screening, Papanicolaou test (Pap test-strongly recommended for 
cervical cancer screening) led to significant reduction in mortality and morbidity in developed countries, where 
proportion of women who are screened by Pap test vary from 68 to 84 per cent. The initiation and sustenance of cervical 
cytology programs involving the screening of sexually active women annually, or once in every 2–5 years, have resulted 
in a large decline in cervical cancer incidence and mortality [5-7]. On the other hand, the screening coverage in Asian 
countries is low and varies from 50 per cent in Singapore with an existing Cancer Screening Program, to 2.6-5 per cent 
in India [8, 9]. As part of the screening program conducted way back in 1995 in Maharashtra, Western India, 
person-to-person and group health education on cervical cancer was provided to 97,000 women in Madha Tehsil, 
Solapur district and results showed a higher proportion of women presented with cervical cancer in earlier stages giving 
scope for intervention to significantly reduce case fatality [10].  
Cytology screening (Pap test) is the standard method used for the screening for cervical cancer, however 
organized screening programs and follow-up are few. The failure of cytological testing in rural India is likely due to a 
number of factors which include (a) poor infrastructure, (b) lack of trained health professionals (c) absence of organized 
community based screening programs and (d) inadequate follow-up of patients with abnormal cervical cytology [11]. 
Some risk factors for cervical cancer are related to lifestyle habits like smoking, obesity, drugs taken for 
reproductive health, oral contraceptive use, etc. It is said that women who have had more than three full-term 
pregnancies or were younger than 17 at the time of their first pregnancy are at higher risk for cervical cancer. Having a 
family history of cervical cancer is a risk factor, especially if a direct relative such as the mother or sister has had 
cervical cancer [12]. Men who have multiple sexual partners or who are carriers of HPV DNA are vectors of high-risk 
HPV types and place their partner at high risk of developing cervical cancer. Sex workers are an important reservoir of 
high-risk HPVs. The role of seminal fluid in the pathogenesis of cervical cancer needs more investigation [13, 14].  
In the past decade, a strong etiologic association between infection with high-risk HPV types and development 
of cervical cancer has been established [15]. Several workers now report that a vast majority of cervical cancer cases are 
caused by infection with certain sub-types of HPV, a sexually transmitted virus that infects cells and may result in 
precancerous lesions and invasive cancer [16].  
HPV is a relatively small, non-enveloped virus; its genome consists of a single molecule of double-stranded, 
circular DNA containing approximately 7,900 bp size. About 100 different sub-types of HPV with distinguished 
variations in its genetic and oncogenic potential are known. The sub-types which precisely affect the anogenital tract are 
reported to be HPV sub-types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 66 and 69 [16, 17]. Vaccines targeting HPV 16 
and 18 have been shown to prevent cervical cancer in cases with persistent HPV infections in clinical trials [18]. 
However, the spectrum of HPV sub types targeted in current vaccine trials is based largely on the prevalence of HPV 
sub types in cancers from the developed world.   
Cervical pathologies and screening programs worldwide 
To date, cervical cancer prevention efforts world-wide have focused on screening sexually active women using 
cytology smears and treating precancerous lesions. It has been widely believed that invasive cervical cancer develops 
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from dysplastic precursor lesions, progressing steadily from mild to moderate, to severe dysplasia (CIN, ASCUS, 
LSIL,HSIL), then to carcinoma in situ, and finally to cancer [19]. It now appears that the direct precursor of cervical 
cancer is high-grade dysplasia, which, in about a third of instances, may progress to cervical cancer over a period of 
10–15 years, while most low-grade dysplasia may regress spontaneously [20].  
In most developed countries, women are advised to have their first smear test soon after becoming sexually 
active and subsequently once every 1–5 years. Many national guidelines are currently moving towards less frequent 
smear tests (once every 3–5 years) because it is recognized that cervical lesions develop slowly over several years. 
Women with low-grade lesions are generally advised to return for routine follow-up smears. Women with high-grade 
precursor lesions are further evaluated via colposcopy, biopsy, and subsequent treatment of confirmed lesions. 
Organized programs with systematic call, recall, follow-up and surveillance systems have had the greatest effect in 
cancer prevention [21]. Currently there are several on-going, cross-sectional studies being carried out on other screening 
approaches such as VIA, VIA with magnification (VIAM), and VILI, as well as HPV testing as alternative screening 
approaches [22]. 
The objectives of this study included increasing the awareness of women regarding cervical screening to 
prevent malignancy of the cervix, to establish organized screening practices, to identify factors for non-screening in 
future and to know the prevalence of various HPV types in our population. Cytological and molecular testing of Pap 
smears was performed; demographic details of the patient like socio-economic status, medical history, lifestyle of the 
woman and her spouse including sexual partners, parity, menstrual history etc. These strategies were aimed at finding 
out the effectiveness of systematic cytology-based screening programs on reducing the number of incidences and 
mortality rate of cervical cancer.  
Materials and Methods 
A community-based sampling of women, 3 years after first sexual activity, was done from the areas in and around 
Hyderabad during the period January 2012–March 2014.  A total of 530 eligible women (based on designed criteria) 
who took part in our camps conducted in collaboration with, Andhra Mahila Sabha (AMS), Shaktishifa Foundation, 
Family Planning Association of India (FPAI), Lions Clubs, and Vasavi Hospitals, participated in our study. Criteria for 
participation: women 19 yrs and above who have been sexually active for more than 3 years, not undergone 
hysterectomy, not pregnant, those who were not menstruating at the time of sampling and those suspected of carrying 
fatal infectious conditions like AIDS or Hepatitis.  
Consent from participants: Informed consent was collected from the subjects. The consent form was read aloud / 
translated to the participants in their native language. Personal and medical history of each of the eligible participants 
was then recorded in a well-designed proforma.  
Counselling: Women were adequately counseled on the health and monetary benefits of availing the 
screening being offered to them as part of the camps.   
Educating nursing staff/medical officers on smear sampling: We trained volunteers, attending nurses at 
health centers during camps who explained the procedure and testing that would be done with the sample. Emphasis 
was made to the medical / para-medical personnel, about the appropriate method of collecting the Pap smear, the 
regions that have to be covered while collecting the smears (ecto and endo-cervical cells), in addition to recording the 
visual impression of the cervix. 
Collection of cervical smears: Of the 720 women who attended our camps, 530 consented to participate and 
were enrolled. The remaining 190 women could not be screened due to non-compliance / non-eligibility for screening. 
Cervical smears were taken by gynecologists with the help of butterfly spatulas on a slide, cells were fixed immediately 
after collecting and processed for cytological evaluation. 
Pap smears Staining: A nuclear stain, Haematoxylin is used to stain cell nuclei. OG-6 counterstain to stain 
  
 
Ivy Union Publishing | http: //www.ivyunion.org December 10, 2016 | Volume 4 | Issue 1  
Thumoju S et al. American Journals of Cancer Biology 2016, 4:6-15 
7 
6 
Page 4 of 10 
the small cells of keratinizing squamous cell carcinoma. Second counterstain, EA-36, stains the superficial epithelial 
squamous cells [23]. Different cytologies were obtained according to Bethesda system of classification for Reporting 
Cervical Cytological Diagnoses. The different cytologies obtained were normal, inflammatory, infection, RCC, atrophic, 
ASCUS, LSIL, HSIL and SCC. 
DNA isolation from cervical smear: Cytobrush was used to collect the cells from both ecto and endo-cervical 
regions. DNA was isolated from the cells collected from the cervix region by our routine salting out method [24].  
HPV Detection 
DNA from 530 patients was screened for the presence HPV by PGMY09/11 primers [25]. PCR products were 
checked on 3% ethidium bromide stained agarose gel. Presence of a 480bp amplicon indicates HPV positivity (Fig 1). 
Known HPV positive control and a negative control were used to rule out the cross contamination and to assess 
satisfactory experimentation.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 1 Lane 1- Sample1 (showing 480bp product), Lane 2-5: Sample2-5 (Negative for HPV), 
Lane 6- Negative control, Lane 7- Positive control (480bp), Lane 8- 100bp Marker 
 
High-risk HPV subtyping 
HPV positive samples (detected by PGMYO9/11) were subjected to high-risk HPV subtyping by high-risk subtyping kit 
(HPV High Risk Typing Sacace Biotechnologies, Catalog # V-25-50F) (Fig 2). Results were interpreted according to the 
manufacturer’s protocol.  
 
 
 
 
 
 
 
 
 
 
 
Fig. 2 Lane 1-3: Sample 1 (Negative for HR-HPV); Lane 5-7: Sample 2 (340bp-HR-HPV 39) 
Lane 9-11: Sample 3 (325bp-HR-HPV 16); Lane 4 & 8: 100bp Marker 
IC: 723bp internal control of β-globin gene 
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Statistical analysis: Statistical analysis was performed using MedCalc software (12.2.1 version), for 
comparison of proportions, to determine significant differences in frequency of cytological types (normal vs other 
cytologies).  Odds Ratio was done for HPV, hr-HPV vs Pap cytologies to estimate the strength of association or level 
of significance (p<0.05).  
Results 
The mean age of women in the study population was 38.73yrs (+ 10.82) with the age range from 19-65 years (Table 1). 
Majority of the women belonged to low and middle (49.6% and 46.2%) socio-economic strata, according to 
socio-economic class. A total of 530 women were screened for Pap smear cytology. Of them, 16.41% cases showed a 
normal cytology with the mean age 31.43yrs (+ 7.47), 43.39% had an inflammatory smear with the mean age 37.95yrs (+ 
9.32), 26.22% showed infection with the mean age 39.01yrs (+ 10.42), 4.15% showed reactive cellular changes with the 
mean age 44.59yrs (+  11.05), 6.41% showed an atrophic smear with the mean age 56.82yrs (+  7.10), 0.75% showed 
ASCUS with the mean age 40.5yrs (+ 8.38), 1.88% showed LSIL with the mean age 39.4yrs (+ 10.42), 0.37% showed 
HSIL with the mean age 46.5yrs (+ 2.12), 0.37% showed squamous cell carcinoma with the mean age 41.5yrs (+ 12.02). 
Figure 3 shows the distribution of different pap cytologies in our study group. 
 
 
Table 1 Demographic details of the subjects 
 
Note: excl: Excluding 
 
 
 
 
No. Variables 
Range Mean+ SD 
Normal 
(n=87) 
Inflammatory 
(n=230) 
Abnormal 
cytology   
(n=213) excl. 
inflammation 
Normal 
(n=87) 
Inflammatory 
(n=213) 
Abnormal 
cytology   
(n=213) excl. 
inflammation 
1 Age (Years) 19-55 19-65 20-65 31.43+7.47 37.95+9.32 42.6+11.8 
2 
Ageat 
Menarche 
(Years) 
10-17 10-18 10-18 12.82+1.322 12.73+1.33 12.93+1.44 
3 
Age at 
Marriage 
(Years) 
6-35 7-31 5-33 17.95+4.12 17.83+4.31 17.36+3.93 
4 
Age at first 
intercourse 
(Years) 
13-35 12-31 12-33 17.95+4.12 18.16+3.86 17.59+3.54 
5 
Age at the first 
child birth 
(Yrs) 
15-36 15-33 14-35 19.65+4.23 19.75+3.84 18.69+3.58 
6 Parity 
(Number) 
0-6 0-9 0-10 3.195+1.590 2.913+1.457 2.553+1.350 
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Table 2 Representing high-risk HPV subtype in different cytologies 
 
Cytology No of cases  
n (%) 
HPV 
n (%) 
No of hr-HPV positive  
n (%) 
hr-HPV subtypes 
NORMAL 87 (16.4) 6 (6.8) 0 - 
INFLAMMATORY 230 (43.3) 17(7.39) 0 - 
INFECTION 139 (26.2) 29 (20.8) 5 (3.5) 16,35,39, 31,45,59,66 
RCC 22 (4.15) 10 (45.4) 2 (9.9) 16 
ATROPHIC 34 (6.41) 6 (17.6) 0 - 
ASCUS 4 (0.75) 3 (75) 0 - 
LSIL 10 (1.88) 3 (30) 0 - 
HSIL 2 (0.3) 2 (100) 1 (50) 52 
SCC 2 (0.3) 2 (100) 2 (100) 16,35 
TOTAL 530 78 (14.7) 10 (12.8)  
 
HPV vs Cytology 
A total of 530 Pap smear samples were screened for presence of HPV, overall 14.7% of HPV positivity was found in 
screened population. HPV was detected in 6.89% of the cases with normal cytology, 7.39% of inflammatory cervix 
cases (p=0.879), 20.86% of cases with cervical infection (OR=3.55, 95%CI, 1.41-8.97, p=0.0071), 45.45% of the cases 
that showed reactive cellular changes (OR=11.2, 95% CI, 3.45-36.60, p=0.0001), 17.64% of cases with atrophy 
(p=0.13), 75% of ASCUS cases (p=0.13), 30% of LSIL (OR=5.78, 95%CI, 1.18-28.27 p=0.03), 50% of HSIL (p=0.004), 
and 100% of cases with squamous cell carcinoma (p=0.001). Of these HPV positive cases, 12.82% (10 out of 78) had 
the presence of hr-HPV sub-types. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 3 Represents prevalance of HPV and hr-HPV in different pap cytologies 
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High-risk HPV Vs Cytology  
High-risk subtypes were present in 5/139 cases (3.59%) with infectious cytology report, 2/22 (9.90%) reported with 
reactive cellular changes, 1/2 (50%) with HSIL, and 2/2 (100%) squamous cell carcinoma (p=0.001) (Table 2). 
 
Of the hr-HPV subtypes, 50% had an infectious cytology, 20% with RCC, 10% with HSIL cytology and 20% 
were SCCs (Fig 3). 
Parity was low in abnormal cases (mean+SD: 2.553+1.350) when compared to cases with normal cytology 
(mean+SD: 3.195+1.590). We did not find any significant difference between normal and abnormal cytologies with 
regard to age at menarche, marriage/age at first intercourse and age at first child birth. The mean age of women showing 
abnormal cytology 42.6 (+11.8) was significantly higher than the mean age of women with a normal pap cytology 31.43 
(+7.47) (Table 1). It is notable that medical history of most of the patients with abnormal pap cytology (RCC, ASCUS, 
LSIL, HSIL and SCC) had diabetes, thyroid disorders and hypertension.  
Discussion 
Cervical cancer remains largely uncontrolled in developing countries such as India because of ineffective patient 
screening and follow-up. Owing to poor awareness and participation, the incidence of invasive cervical cancer remains 
high, especially in rural India, despite the availability of Pap testing on an opportunistic basis [26]. 
In India, there are few organized or high-level opportunistic screening programs for cervical cancer in some of 
the states. There have been a few success stories of effective screening and prevention of cervical cancer from some 
parts of the country. Efforts to improve awareness in the population have resulted in early detection and improved 
survival from cervical cancer in a backward rural region in western India [27, 28]. Data from population-based cancer 
registries in different regions indicate a slow, but steady, decline in the incidence of cervical cancer. However, the rates 
are still too high, particularly in the rural areas, and the absolute number of cases is on the rise. 
We encountered initial high rates of non-compliance (5.86%) from the participants in our camps owing in part, 
to ignorance of the importance of cervical screening and due to the stigma associated with a pelvic examination, per se. 
After the few initial camps, we adopted the strategy of counselling the participants before the pap smear was collected, 
on how safe the procedure was, about usefulness of the test in avoiding future risk for cancer and that women should 
make use of the free service while it was being offered as a part of our project; maximum participation with hardly any 
drop-outs were seen after pre-test counselling was done. Through local medical officers, other para-medical volunteers, 
it was possible to reach remote areas with support from Family Planning Association India, Lions Club, Andhra Mahila 
Sabha and Vasavi Hospital.  
Advanced / precancerous lesions of the cervix were seen mostly in patients over the age of 40 years; it is 
notable from our data that most of the women who showed a normal cervix upon examination were around the age of 
30 years. Cervical tissue seems to heal well in the earlier age group but with increasing age becomes more prone to 
pathological tissue changes. The same could be said keeping in view HPV infection – only persistent infection with 
HPV, associated with later age was a risk factor for cervical malignancy. Unlike other subjects who showed increased 
parity as a risk factor, our results show that lower parity seems to be associated with a pathological cervix as compared 
to cases with higher parity. This suggested that hormonal factors associated with cervix, i.e. lesser exposure of cervix to 
pregnancy-related hormones was probably a risk factor. Patients who showed the presence of hr-HPV, all had the 
medical history like diabetes, thyroid dysfunction etc., making the cervical tissue more prone to infection and associated 
inflammation. Immunological response of cervical tissue is better in early age and hence low infection and lesser scope 
for persistence of HPV infection as seen from our results is associated with a normal cervical cytology.  
Of the cases that tested positive for hr-HPV subtypes, 40% had diabetes, 20% cases had altered thyroid levels. 
A higher incidence of infections is seen in patients with diabetes due to the hyperglycemic environment which promotes 
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immune dysfunction. There is low production of interleukins and reduced antimicrobial activity [29]. These effects of 
hyperglycemia are seen in all tissues and organs; one of the common infection-prone regions is the vagina (fungal or 
bacterial or protozoan infections). These factors may contribute to persistence of HPV infection in the cervix, leading to 
transforming squamous epithelial cells to malignant forms.   
Cervical cytology is considered to be a very specific test for high-grade precancerous lesions or cancer but, 
even if the quality of collection and spreading of cells, fixation, and staining of smears, and reporting by well-trained 
technicians and cytopathologists are good, its sensitivity is only moderate. So co-testing for the presence of HPV 
high-risk subtypes was done to improve the chances for detecting an abnormal cervix (given the etiological role for 
HPV in cervical malignancy). Routine cervical screening programs do not include HPV testing for reporting the risk 
and/or the need for intensive follow-up, in a patient. Further, because geographical variation in the sub-type distribution 
may exist, knowledge about the distribution of HPV types in cervical cancers and HPV types circulating in the 
communities in different regions of India would be useful in devising the optimal strategy for vaccination in our 
population [30]. 
High-risk subtypes 16, 31, 35, 39, 45, 52, 59, 66 have been seen in our cases; subtype 66 is not reported often 
from our population. While 16 was the most prevalent subtype either singly or existing as multiple infection with other 
subtypes, high-risk subtype 35 was seen to be next to subtype 16 (Table 2). HPV infection was seen mostly in cases 
where the Pap smear showed an infectious cytology, in addition to the cases with reactive cellular changes or other 
precancerous lesions (LSIL, HSIL). Among healthy women, a HPV infection is known to clear within 1–2 years. Our 
cases which showed presence of high-risk HPVs have been put on follow-up program to monitor the changes in the 
cervix by repeated pap and colposcopy where warranted. 
Organizing camps and creating awareness by educating the volunteers and subjects who participate in these 
camps, educating the medical / para-medical staff in local health centers regarding the appropriate screening practices 
and suitable patient follow-up based on the pap cytology report and HPV testing can considerably reduce the burden of 
cervical cancer in our population. 
Conclusion 
Although cytological screening is being carried out, there are no organized programs and the testing is often of poor 
quality and performed inadequately and inefficiently among the population. The findings from research on various 
approaches to screening (in terms of accuracy and effectiveness) should be taken into account when considering 
reorganizing existing programs. Women should take active part and be concerned with issues dealing with their health 
and personal hygiene, awareness is the first step towards getting involved in cancer prevention. Information on the 
presence of hr-HPV subtypes other than 16 and 18 prevalent in our population should be used to device adequate 
vaccination strategies suitable for our population.   
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